Evaluation of the Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5-FU/Oxaliplatin-Based Regimens in E3200
OBJECTIVES:
- Determine the CpG island methylation pathway markers that are adverse for survival
after treatment with fluorouracil in patients with advanced colorectal adenocarcinoma
treated with fluorouracil and oxaliplatin with or without bevacizumab on clinical trial
E-3200.
- Compare the methylation results to clinicopathologic and molecular findings and
survival.
OUTLINE: This is a multicenter study.
Tissue, blood, and urine samples and genomic DNA samples from tumor tissue blocks are
examined by pyrosequencing assay for methylation. Genes examined include MINT1, MINT31, P14,
and P16. Microsatellite instability and loss of heterozygosity (LOH) on chromosome 18 (18q
LOH) are also assessed. Microsatellites examined include BAT loci, TGFβRII, D2S123, D55346,
and D17S250.
PROJECTED ACCRUAL: A total of 350 specimens will be accrued for this study.
Observational
N/A
Progression-free survival
No
Stanley Hamilton, MD
Study Chair
M.D. Anderson Cancer Center
Unspecified
CDR0000534281
NCT00897819
Name | Location |
---|